TABLE 2. Most commonly reported symptoms* after receipt of recombinant zoster vaccine (RZV) in reports submitted to VAERS (N = 4,381)† — United States, October 2017–June 2018.
| Sign/Symptom | Total RZV reports, no. (%) | RZV given in combination with other vaccines, no. (%) |
|---|---|---|
| Pyrexia |
1,034 (23.6) |
57 (26.6) |
| Injection site pain |
985 (22.5) |
49 (22.9) |
| Injection site erythema |
880 (20.1) |
50 (23.4) |
| Pain |
853 (19.5) |
45 (21.0) |
| Chills |
847 (19.3) |
32 (15.0) |
| Headache |
730 (16.7) |
30 (14.0) |
| Fatigue |
703 (16.0) |
23 (10.7) |
| Pain in extremity |
691 (15.8) |
37 (17.3) |
| Injection site swelling |
588 (13.4) |
29 (13.6) |
| Myalgia | 530 (12.1) | 19 (8.9) |
Abbreviation: VAERS = Vaccine Adverse Event Reporting System.
* According to Medical Dictionary for Regulatory Activities Preferred Terms, a single report may be assigned more than one Preferred Term (i.e., terms are not mutually exclusive).
† Includes reports for RZV given alone (95.1%) and concomitantly with other vaccines.